Pfizer Inc PFE

$28.06 -0.41 (-1.44%)

Valuation

Market cap
162,274,848,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.46
P/E (forward)
9.48
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
37,656,300
Avg volume
33,660,148
Day's range
$28.00 – $28.54
Shares out
5,699,854,000
Stochastic %K
3%
Beta
0.31
Analysts
Hold
Price target
$30.56

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Bobear12 Nov 18, 10:35 PM
$PFE /could MDGL troubling news start to create interest in GALT? What are the chances for fast track approval from the FDA?
0 replies
Bobear12 Nov 18, 10:21 PM
$PFE thought you should know. Galectin Therapeutics Inc. (GALT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy).
0 replies
smartfellar Nov 18, 8:42 PM
$PFE the guys on wall street all talk to each other. im sure there are one or two guys who manage the covered call strategy at one or two big firms, and have vast resources to keep this pinned right where they want it, and the other firms know not to ruffle feathers so they stay out while us retail traders get sniped
1 replies
MrPeanutEsquire Nov 18, 8:36 PM 1 replies
JoinTheDiscussionGroup67 Nov 18, 7:20 PM
💊 Pharmaceutical Stocks: Innovation and Patent Strategy Matter Large pharmaceutical companies depend on drug development, commercial execution, and successful product pipelines. $ABBV (AbbVie) has exposure to immunology and neuroscience treatments, while $REGN (Regeneron) focuses on biotechnology and innovative medicines. $PFE (Pfizer) continues developing its pharmaceutical and vaccine portfolio. Clinical results, patent expirations, new product launches, and revenue guidance are important factors.
0 replies
Techdamentals Nov 18, 6:57 PM
Nvidia's results lifted chip stocks before the open on Wednesday, November 18, 2026, while the Dow fell about 1% in morning trading as health care stocks slid. One number from $PFE's latest report: revenue was $16.583 billion in the third quarter of 2026, down 0.4% from $16.654 billion, while research and development spending rose 18% to $3.016 billion. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator lays out revenue, margins, cash and debt from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. See the fundamentals below 👇 https://techdamentals.com/v3/PFE?ref=st
0 replies
dom04 Nov 18, 6:53 PM
$PFE ohhh pfizer, you touch your support line, time to bounce to new high!
1 replies
1hawk Nov 18, 6:21 PM
$PFE why you dont chase
0 replies